Literature DB >> 8931005

Glutamate decarboxylase-67 messenger RNA expression in normal human basal ganglia and in Parkinson's disease.

A P Nisbet1, D J Eve, A E Kingsbury, S E Daniel, C D Marsden, A J Lees, O J Foster.   

Abstract

Expression of glutamate decarboxylase-67 messenger RNA was examined in the basal ganglia of normal controls and of cases of Parkinson's disease using in situ hybridization histochemistry in human post mortem material. In controls glutamate decarboxylase-67 messenger RNA expression was detected in all large neurons in both segments of the globus pallidus and in three neuronal subpopulations in the striatum as well as in substantia nigra reticulata neurons and in a small sub-population of subthalamic neurons. In Parkinson's disease, there was a statistically significant decrease of 50.7% in glutamate decarboxylase-67 messenger RNA expression per neuron in the lateral segment of the globus pallidus (controls: mean 72.8 microns2 +/- S.E.M. 8.7 of silver grain/neuron, n = 12; Parkinson's disease: mean 35.9 microns2 +/- S.E.M. 9.7 of silver grain/neuron, n = 9, P = 0.01, Student's t-test). In the medial segment of the globus pallidus, there was a small, but non-significant decrease of glutamate decarboxylase-67 messenger RNA expression in Parkinson's disease (controls: mean 100.6 microns2 +/- S.E.M. 7.2 of silver grain/neuron, n = 11; Parkinson's disease: mean 84.8 microns2 +/- S.E.M. 13.0 of silver grain/neuron, n = 7, P = 0.1, Student's t-test). No significant differences in glutamate decarboxylase-67 messenger RNA were detected in striatal neuronal sub-populations between Parkinson's disease cases and controls. These results are the first direct evidence in humans that there is increased inhibitory drive to the lateral segment of the globus pallidus in Parkinson's disease, as suggested by data from animal models. We therefore provide theoretical support for current experimental neurosurgical approaches to Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8931005     DOI: 10.1016/0306-4522(96)00299-0

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  5 in total

1.  Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.

Authors:  A Colzi; K Turner; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

2.  Decreased glutamic acid decarboxylase mRNA expression in prefrontal cortex in Parkinson's disease.

Authors:  Amélie C Lanoue; Alexandra Dumitriu; Richard H Myers; Jean-Jacques Soghomonian
Journal:  Exp Neurol       Date:  2010-09-09       Impact factor: 5.330

3.  Subthalamic stimulation evokes complex EPSCs in the rat substantia nigra pars reticulata in vitro.

Authors:  Ke-Zhong Shen; Steven W Johnson
Journal:  J Physiol       Date:  2006-04-13       Impact factor: 5.182

4.  New insights into {gamma}-aminobutyric acid catabolism: Evidence for {gamma}-hydroxybutyric acid and polyhydroxybutyrate synthesis in Saccharomyces cerevisiae.

Authors:  Benoît Bach; Emmanuelle Meudec; Jean-Paul Lepoutre; Tristan Rossignol; Bruno Blondin; Sylvie Dequin; Carole Camarasa
Journal:  Appl Environ Microbiol       Date:  2009-05-01       Impact factor: 4.792

5.  Subchronic neurotoxicity of diazinon in albino mice: Impact of oxidative stress, AChE activity, and gene expression disturbances in the cerebral cortex and hippocampus on mood, spatial learning, and memory function.

Authors:  Asieh Karimani; Nasrin Ramezani; Amir Afkhami Goli; Mohammad Hossein Nazem Shirazi; Hosein Nourani; Amir Moghaddam Jafari
Journal:  Toxicol Rep       Date:  2021-06-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.